OnCo
technologiesTechnologyStandard of care

HRD & BRCA testing

Tests that reveal whether a tumour has a broken DNA repair system, which predicts response to PARP inhibitors and platinum.

Germline and somatic BRCA1/2 sequencing plus genomic-scar scores (myChoice CDx GIS, FoundationOne LOH) define HRD. Functional assays (RAD51 foci) and mutational signature 3 are emerging alternatives that may capture reversion.

Schematic · not to scale
Unrepaired double-strand break · Genomic scars (LOH, TAI, LST)

How it works

Loss of heterozygosity, telomeric allelic imbalance, and large-scale transitions summed into a genomic instability score.

Strengths
  • Extends PARP-inhibitor benefit beyond BRCA carriers
Limitations
  • Scar is permanent even after resistance emerges
  • Threshold debates

Key papers

1top

Latest papers

top
Literature trend408 papers in the last 12 months+30% vs prior 12How this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"homologous recombination deficiency" OR ABSTRACT:"homologous recombination deficiency" OR TITLE:"HRD testing" OR ABSTRACT:"HRD testing" OR TITLE:"HRD score" OR ABSTRACT:"HRD score"). Results are unfiltered search hits about HRD & BRCA testing, not a curated reading list.

Connected

16top

Pages like this

not linked directly; found by shared links